An experimental diabetes and obesity drug, enicepatide, produced encouraging mid-stage results. These are preliminary sponsor-reported findings, not proof of longer life or fewer heart attacks.
What changed
On September 22, 2026, Roche announced results from CT-388-104. At 48 weeks, the highest-dose group had average weight loss of 15.5% and an HbA1c decline of 2.65 percentage points from baseline. These are within-group changes, not placebo-adjusted differences.
How strong is the evidence?
Human randomized evidence, reported by the sponsor: the double-blind, placebo-controlled phase II trial enrolled 447 adults with type 2 diabetes and overweight or obesity. This brief relies on Roche’s announcement; a peer-reviewed results paper and its publication date were not verified. Roche has a commercial interest in the drug.
What remains uncertain
The announcement does not provide full placebo comparisons or confidence intervals. Gastrointestinal symptoms were the most common adverse events. Long-term safety and cardiovascular benefits remain unestablished; HbA1c and weight are not direct measures of heart attacks or survival.
Why it matters
The findings justify further investigation, not treatment changes. When reading drug headlines, ask whether results describe improvement from baseline or benefit over a comparison group. Those answer different questions.
Sources
Roche results announcement, September 22, 2026. Trial identifier: NCT06628362.
